Granisetron
HCI Injection
| General Information: Granisetron hydrochloride injection is typically utilized in the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy. For indications, dosing and other information, please refer to the manufacture package insert.
|
| |
| Manufacturer |
Products |
Size |
NDC |
PI |
MSDS |
| Sagent |
Granisetron INJ
Preservative Free |
1mg/mL, 4mL MDV |
25021-0779-01 |
PI |
MSDS |
| Sagent |
Granisetron INJ |
1mg/mL, 4mL |
25021-0781-04 |
PI |
MSDS |
| |
|
|
|
|
|
|
Wockhardt |
Granisetron HCI INJ |
1mg/mL, 1mL SDV |
64679-0661-03 |
PI |
MSDS |
| Wockhardt |
Granisetron HCI INJ |
1mg/mL, 4mL MDV |
64679-0661-02 |
PI |
MSDS |
|
| |
| Clinical Data:
For any questions or for further
information related to Granisetron Hydrochloride Injection,
clinical pharmacology, additional indications and
usages, contraindications,
warnings, precautions, adverse
reactions, dosage,
administration and/or storage
of this product, please
contact
BDI Pharma or
call
1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |